Skip to main content
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. — Investor Relations & Filings

Ticker · PPCB ISIN · US74346N4043 LEI · 549300Q3HY827FNV8Y56 US Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2020-09-29 Regulatory Filings
Country US United States of America
Listing US PPCB

About Propanc Biopharma, Inc.

https://www.propanc.com/

Propanc Biopharma, Inc. is a clinical-stage company developing cancer treatments focused on preventing tumor recurrence and metastasis. Its lead candidate, PRP, is a pancreatic proenzyme formulation designed to target and eradicate cancer stem cells. The therapeutic approach aims to suppress tumor progression by controlling cancer cell migration, inhibiting the formation of tumor blood vessels, and inducing cell death. The company's primary focus is on developing long-term therapies for patients with solid tumors, such as pancreatic cancer.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25 Notification of Late Filing submitted to the SEC. It specifically states that the company, Propanc Biopharma, Inc., was unable to file its Annual Report on Form 10-K for the year ended June 30, 2020, by the due date and requests an extension. The document does not contain the actual 10-K report or financial data but is a notification about the delay in filing the 10-K. According to the rules, such a notification is a regulatory filing and not the report itself. Therefore, the correct classification is Regulatory Filings (RNS).
2020-09-29 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 3 to a Form S-1 Registration Statement filed with the SEC. Form S-1 is used for registering securities for public offering under the Securities Act of 1933. The text includes detailed information about the securities being registered, the offering price, the selling stockholder, and other offering details. It is a registration statement amendment, not a financial report, earnings release, or other types of filings. This type of document is best classified under Capital/Financing Update (CAP) because it relates to the company's fundraising and securities offering activities.
2020-08-13 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter from the company to the SEC responding to comments on an Amendment No. 2 to a Registration Statement on Form S-1. It discusses revisions to the registration statement and plans to file Amendment No. 3. The content is correspondence related to a regulatory filing process, specifically about a registration statement for securities offering. The document length is short (2088 characters) and it is a response letter, not the registration statement itself or a financial report. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and correspondence with the SEC that do not fit other categories.
2020-08-13 English
Regulatory Filings 2020
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify this document as any specific filing type. According to the fallback rule, when a document does not fit any specific category or lacks sufficient information, it should be classified as a Regulatory Filing (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable. Therefore, the best classification is RNS with moderate confidence due to lack of readable content.
2020-08-07 English
Proxy Solicitation & Information Statement 2020
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14C Information Statement filed pursuant to Rule 14c-101 under the Securities Exchange Act of 1934. It is titled as an Information Statement and explicitly states it is not a notice of a meeting nor a proxy solicitation. The content describes the approval by written consent of a reverse stock split amendment to the Certificate of Incorporation. The document is detailed, over 15,000 characters, and contains substantive information about the corporate action, voting results, and legal background. This type of filing is a Proxy Solicitation & Information Statement (PSI), as it provides information to shareholders to inform them of corporate actions and solicit votes or consents, even if no meeting is held. It is not an announcement of a report, nor a full annual or quarterly report, nor a regulatory filing or announcement. Therefore, the correct classification is PSI with high confidence.
2020-08-05 English
Regulatory Filings 2020
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Due to the lack of identifiable information and the inability to determine the nature of the document, it cannot be classified into any specific filing category based on the given text. According to the rules, when a document does not neatly fit into any specific category, it should be classified as a Regulatory Filing (RNS), which serves as a fallback category.
2020-07-31 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.